NACTN, a collaboration of university neurosurgical teams, is led by Robert Grossman, MD, a professor of neurosurgery at The Methodist Hospital Neurosurgical Institute in Houston.
The funding will support Phase 2 and 3 trials of the drug Riluzole, an FDA-approved neuroprotective drug. Riluzole is designed to limit spinal cord damage.
More Articles on Spine:
NASS Advocacy Documentary Calls for More Spine Specialist Involvement
2 Laser Spine Institute Studies on Lumbar Spinal Stenosis Treatments Published
6 Opportunities for Spine Surgeons to Forward the Field
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
